Obagi Medical presents clinical data at Nashville dermatology conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
May 15, 2026 8:13 AM EDTData from the ALOHA Program and NU-GEN Cellular Renewal Serum Showcase Results to Help Drive Practice Success
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN.
Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and... More